Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT)
- 190 Downloads
To evaluate the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT).
From March 2013 to August 2016, we retrospectively analyzed 1124 benign prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with continuous single antiplatelet (AP) therapy (group B); 41 patients treated with single AP therapy but intermittent during preoperative time (group C) and 955 cases had no AP therapy (group D). Patients’ baseline characteristics, 1-year clinical outcomes, rates of postoperative bleeding and complications were presented in this study.
All patients received successful operations and no severe postoperative complications occurred. Only one patient in Group D required transfusion. The enucleation time and catheterization time for the DAPT patients were the longest among four groups (p < 0.001, respectively). The overall complications rates within 30 days were 23.2% (13/56) in Group A, 27.8% (20/72) in Group B, 19.5% (8/41) in Group C, and 27.0% (258/955) in Group D, respectively (p = 0.678). By the 12 months, the international prostate symptom scores (IPSS), quality of life scores (QOL) and residual urine volume (RUV) in all groups have been significantly improved.
HoLEP in patients receiving DAPT after coronary artery stunting showed similar results to those achieved in patients receiving single AP therapy or non-AP therapy. It can be a good option, which the urologists can offer to those patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.
KeywordsBenign prostate hyperplasia Lower urinary tract symptoms Holmium laser enucleation of the prostate Dual antiplatelet therapy
Benign prostatic hyperplasia
Holmium laser enucleation of the prostate
Transurethral resection of the prostate
Photoselective vaporization of the prostate
Coronary artery bypass grafts
Dual antiplatelet treatment
Post-void residual urine
We gratefully acknowledge the urologists making great contributions to the prostatic laser surgery, especially YiRan Huang and Gilling PJ.
SJ: Project development and manuscript writing. SA: Data collection and analysis, and manuscript writing. TZ: Data collection and management. XW: Project development and manuscript editing.
The authors declare that they have no funding.
Compliance with ethical standards
Institutional Review Board approval of Renji Hospital affiliated to Shanghai JiaoTong University, Medical school was obtained for the retrospective study and patient written informed consent was obtained.
Consent to publish
All of the details can be published and consent for publication was not required for this study.
Availability of data and materials
The datasets during the current study were available from the corresponding author on reasonable request.
Conflict of interest
The authors declare that they have no competing interests.
- 3.Windecker S, Kolh P, Alfonso F et al (2014) ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefPubMedGoogle Scholar